Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2014, Article ID 801072, 4 pages
http://dx.doi.org/10.1155/2014/801072
Case Report

Possible Association of Etanercept, Venous Thrombosis, and Induction of Antiphospholipid Syndrome

1Internal Medicine, Michigan State University, 138 Service Road, A225 Clinical Center, East Lansing, MI 48825, USA
2Internal Medicine and Hematology/Oncology, McLaren of Greater Lansing, 401 West Greenlawn Avenue, Lansing, MI 48910, USA
3Internal Medicine and Rheumatology, Michigan State University, 138 Service Road, A225 Clinical Center, East Lansing, MI 48825, USA

Received 30 March 2014; Accepted 29 April 2014; Published 15 May 2014

Academic Editor: Masataka Kuwana

Copyright © 2014 Shanti Virupannavar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Ramos-Casals, P. Brito-Zerón, S. Muñoz et al., “Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases,” Medicine, vol. 86, no. 4, pp. 242–251, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Golmia and M. Scheinberg, “Infliximab use and sequential occurrence of autoantibodies and neoplasia in a patient with spondyloarthritis,” Revista Brasileira de Reumatologia, vol. 50, no. 6, pp. 723–728, 2010. View at Google Scholar · View at Scopus
  3. H. Yoshida, C. E. Yilmaz, and D. N. Granger, “Role of tumor necrosis factor-α in the extraintestinal thrombosis associated with colonic inflammation,” Inflammatory Bowel Diseases, vol. 17, no. 11, pp. 2217–2223, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Atzeni, M. Turiel, F. Capsoni, A. Doria, P. Meroni, and P. Sarzi-Puttini, “Autoimmunity and anti-TNF-α agents,” Annals of the New York Academy of Sciences, vol. 1051, pp. 559–569, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Caramaschi, D. Biasi, M. Colombatti et al., “Anti-TNFα therapy in rheumatoid arthritis and autoimmunity,” Rheumatology International, vol. 26, no. 3, pp. 209–214, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. M. C. Genovese, J. M. Bathon, R. M. Fleischmann et al., “Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis,” Journal of Rheumatology, vol. 32, no. 7, pp. 1232–1242, 2005. View at Google Scholar · View at Scopus
  7. M. Lebwohl, A. Gottlieb, W. Wallis, and R. Zitnik, “Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis,” Journal of the American Academy of Dermatology, vol. 52, article 195, 2005. View at Google Scholar
  8. M. Aringer, F. Houssiau, C. Gordon et al., “Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients,” Rheumatology, vol. 48, no. 11, pp. 1451–1454, 2009. View at Google Scholar · View at Scopus
  9. T. Reitblat and O. Reitblat, “Appearance of ANCA-associated vasculitis under tumor necrosis factor-alpha inhibitors treatment,” American Journal of Case Reports, vol. 14, pp. 80–82, 2013. View at Google Scholar
  10. V. L. Williams and P. R. Cohen, “TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists,” International Journal of Dermatology, vol. 50, no. 5, pp. 619–625, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. A. T. Borchers, N. Leibushor, G. S. Cheema, S. M. Naguwa, and M. E. Gershwin, “Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases,” Journal of Autoimmunity, vol. 37, no. 4, pp. 273–288, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. M. de Bandt, J. Sibilia, X. le Loët et al., “Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey,” Arthritis Research & Therapy, vol. 7, no. 3, pp. R545–R551, 2005. View at Google Scholar · View at Scopus
  13. S. Vermeire, M. Noman, G. van Assche et al., “Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn's disease: a prospective cohort study,” Gastroenterology, vol. 125, no. 1, pp. 32–39, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. L. de Rycke, E. Kruithof, N. van Damme et al., “Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy,” Arthritis and Rheumatism, vol. 48, no. 4, pp. 1015–1023, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Antivalle, M. G. Marazza, G. Randisi, P. Sarzi-Puttini et al., “Long term treatment of rheumatoid arthritis with infliximab: efficacy, side effects and autoantibodies induction,” Arthritis & Rheumatology, vol. 46, article 534, 2002. View at Google Scholar
  16. J. A. Mendoça, J. F. Marques-Neto, A. M. Samara, and S. Apenzeller, “Increased levels of rheumatoid factors after TNF inhibitor in rheumatoid arthritis,” Rheumatology International, vol. 32, pp. 815–818, 2012. View at Google Scholar
  17. C. Ferraro-Peyret, F. Coury, J. G. Tebib, J. Bienvenu, and N. Fabien, “Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study,” Arthritis Research & Therapy, vol. 6, no. 6, pp. R535–R543, 2004. View at Google Scholar · View at Scopus
  18. F. Bobbio-Pallavicini, C. Alpini, R. Caporali, S. Avalle, S. Bugatti, and C. Montecucco, “Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment,” Arthritis Research & Therapy, vol. 6, no. 3, pp. R264–R272, 2004. View at Google Scholar · View at Scopus
  19. F. Atzeni, R. Talotta, F. Salaffi et al., “Immunogenicity and autoimmunity during anti-TNF therapy,” Autoimmunity Reviews, vol. 12, pp. 703–708, 2013. View at Google Scholar
  20. C. Eriksson, S. Engstrand, K.-G. Sundqvist, and S. Rantapää-Dahlqvist, “Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα,” Annals of the Rheumatic Diseases, vol. 64, no. 3, pp. 403–407, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Jonsdottir, J. Forslid, A. van Vollenhoven et al., “Treatment with tumour necrosis factor α antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies,” Annals of the Rheumatic Diseases, vol. 63, no. 9, pp. 1075–1078, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Petitpain, N. Gambier, D. Wahl, I. Chary-Valckenaere, D. Loeuille, and P. Gillet, “Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006,” Bio-Medical Materials and Engineering, vol. 19, no. 4-5, pp. 355–364, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. P. L. Masson, “Thromboembolic events and anti-tumor necrosis factor therapies,” International Immunopharmacology, vol. 14, pp. 444–445, 2012. View at Google Scholar
  24. A. Makol, M. Grover, C. Guggenheim, and H. Hassouna, “Etanercept and venous thromboembolism: a case series,” Journal of Medical Case Reports, vol. 4, article 12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. L. A. Korswagen, G. M. Bartelds, C. L. M. Krieckaert et al., “Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study,” Arthritis and Rheumatism, vol. 63, no. 4, pp. 877–883, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Miyakis, M. D. Lockshin, T. Atsumi et al., “International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS),” Journal of Thrombosis and Haemostasis, vol. 4, no. 2, pp. 295–306, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Dedeoglu, “Drug-induced autoimmunity,” Current Opinion in Rheumatology, vol. 21, no. 5, pp. 547–551, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Davies, J. B. Galloway, K. D. Watson et al., “Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register,” Annals of the Rheumatic Diseases, vol. 70, no. 10, pp. 1831–1834, 2011. View at Publisher · View at Google Scholar · View at Scopus